LRRK2 and Parkinson disease: Besides, LRRK2 promotes mitochondrial alteration in microglia via Drp1 in a kinase-dependent manner, contributing to pro-inflammatory responses, which is regarded as a potential therapeutic target in PD (Ho et al., 2018).